Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases

Additional Individual Contributors Of The Ucdc And The E-Imd Consortium

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts. Aims: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs. Methods: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases. Results: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients. Conclusions: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilising differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalJournal of Inherited Metabolic Disease
DOIs
StateAccepted/In press - Jul 4 2018

Fingerprint

Rare Diseases
Urea
Research
Inborn Urea Cycle Disorder
Ornithine Carbamoyltransferase Deficiency Disease
Databases
Information Storage and Retrieval
Natural History
Prenatal Diagnosis
Ammonium Compounds
Liver Transplantation
Sample Size
Outcome Assessment (Health Care)
Newborn Infant
Phenotype
Therapeutics
Population

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases. / Additional Individual Contributors Of The Ucdc And The E-Imd Consortium.

In: Journal of Inherited Metabolic Disease, 04.07.2018, p. 1-13.

Research output: Contribution to journalArticle

@article{63ecaf65893741e284b2c9f88b73ad3d,
title = "Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases",
abstract = "Background: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts. Aims: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs. Methods: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases. Results: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9{\%}) or by high-risk family screening (24.7{\%}), and less often by newborn screening (8.9{\%}) and prenatal testing (3.7{\%}). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients. Conclusions: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilising differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.",
author = "{Additional Individual Contributors Of The Ucdc And The E-Imd Consortium} and Roland Posset and Garbade, {Sven F.} and Nikolas Boy and Burlina, {Alberto B.} and Carlo Dionisi-Vici and Dries Dobbelaere and Angeles Garcia-Cazorla and {de Lonlay}, Pascale and Teles, {Elisa Le{\~a}o} and Roshni Vara and {Ah Mew}, Nicholas and Batshaw, {Mark L.} and Baumgartner, {Matthias R.} and Shawn McCandless and Jennifer Seminara and Marshall Summar and Hoffmann, {Georg F.} and Stefan K{\"o}lker and Peter Burgard and Berry, {Susan A.} and Lindsay Burrage and Curtis Coughlin and Diaz, {George A.} and Gallagher, {Renata C.} and Andrea Gropman and Cary Harding and Brendan Lee and {Le Mons}, Cynthia and Merritt, {J. Lawrence} and Nagamani, {Sandesh C.S.} and Andreas Schulze and Tamar Stricker and Mendel Tuchman and Susan Waisbren and James Weisfeld-Adams and Derek Wong and Marc Yudkoff and Arnoux, {Jean Baptiste} and Ivo Barić and Bosch, {Annet M.} and Brigitte Chabrol and Anupam Chakrapani and Elisenda Cort{\`e}s-Saladefont and Couce, {Maria L.} and {de Laet}, Corine and {de Meirleir}, Linda and Francois Eyskens and Peter Freisinger and Florian Gleich and Stephanie Gr{\"u}newald",
year = "2018",
month = "7",
day = "4",
doi = "10.1007/s10545-018-0222-z",
language = "English (US)",
pages = "1--13",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases

AU - Additional Individual Contributors Of The Ucdc And The E-Imd Consortium

AU - Posset, Roland

AU - Garbade, Sven F.

AU - Boy, Nikolas

AU - Burlina, Alberto B.

AU - Dionisi-Vici, Carlo

AU - Dobbelaere, Dries

AU - Garcia-Cazorla, Angeles

AU - de Lonlay, Pascale

AU - Teles, Elisa Leão

AU - Vara, Roshni

AU - Ah Mew, Nicholas

AU - Batshaw, Mark L.

AU - Baumgartner, Matthias R.

AU - McCandless, Shawn

AU - Seminara, Jennifer

AU - Summar, Marshall

AU - Hoffmann, Georg F.

AU - Kölker, Stefan

AU - Burgard, Peter

AU - Berry, Susan A.

AU - Burrage, Lindsay

AU - Coughlin, Curtis

AU - Diaz, George A.

AU - Gallagher, Renata C.

AU - Gropman, Andrea

AU - Harding, Cary

AU - Lee, Brendan

AU - Le Mons, Cynthia

AU - Merritt, J. Lawrence

AU - Nagamani, Sandesh C.S.

AU - Schulze, Andreas

AU - Stricker, Tamar

AU - Tuchman, Mendel

AU - Waisbren, Susan

AU - Weisfeld-Adams, James

AU - Wong, Derek

AU - Yudkoff, Marc

AU - Arnoux, Jean Baptiste

AU - Barić, Ivo

AU - Bosch, Annet M.

AU - Chabrol, Brigitte

AU - Chakrapani, Anupam

AU - Cortès-Saladefont, Elisenda

AU - Couce, Maria L.

AU - de Laet, Corine

AU - de Meirleir, Linda

AU - Eyskens, Francois

AU - Freisinger, Peter

AU - Gleich, Florian

AU - Grünewald, Stephanie

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Background: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts. Aims: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs. Methods: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases. Results: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients. Conclusions: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilising differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

AB - Background: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts. Aims: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs. Methods: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases. Results: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients. Conclusions: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilising differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

UR - http://www.scopus.com/inward/record.url?scp=85049566261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049566261&partnerID=8YFLogxK

U2 - 10.1007/s10545-018-0222-z

DO - 10.1007/s10545-018-0222-z

M3 - Article

AN - SCOPUS:85049566261

SP - 1

EP - 13

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

ER -